EyePoint Pharmaceuticals Inc’s filing revealed that its Director Zaderej Karen L. acquired Company’s shares for reported $29950.0 on May 19 ’25. In the deal valued at $5.99 per share,5,000 shares were bought. As a result of this transaction, Zaderej Karen L. now holds 36,500 shares worth roughly $0.35 million.
Then, Zaderej Karen L. bought 5,000 shares, generating $29,050 in total proceeds. Upon buying the shares at $5.81, the Director now owns 31,500 shares.
Before that, Zaderej Karen L. bought 5,000 shares. EyePoint Pharmaceuticals Inc shares valued at $27,350 were divested by the Director at a price of $5.47 per share. As a result of the transaction, Zaderej Karen L. now holds 26,500 shares, worth roughly $0.25 million.
RBC Capital Mkts initiated its EyePoint Pharmaceuticals Inc [EYPT] rating to an Outperform in a research note published on June 17, 2025; the price target was $28. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Scotiabank began covering EYPT with “Sector outperform” recommendation on October 16, 2024. Jefferies started covering the stock on August 28, 2024. It rated EYPT as “a Buy”.
Price Performance Review of EYPT
On Monday, EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] saw its stock fall -2.37% to $9.49. Over the last five days, the stock has lost -1.56%. EyePoint Pharmaceuticals Inc shares have risen nearly 18.48% since the year began. Nevertheless, the stocks have risen 27.38% over the past one year. While a 52-week high of $13.98 was reached on 06/25/25, a 52-week low of $3.91 was recorded on 04/09/25.
Levels Of Support And Resistance For EYPT Stock
The 24-hour chart illustrates a support level at 9.30, which if violated will result in even more drops to 9.10. On the upside, there is a resistance level at 9.84. A further resistance level may holdings at 10.18.
How much short interest is there in EyePoint Pharmaceuticals Inc?
A steep rise in short interest was recorded in EyePoint Pharmaceuticals Inc stocks on 2025-06-13, dropping by -0.47 million shares to a total of 6.74 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 7.21 million shares. There was a decline of -6.95%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 22, 2024 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $35 price target.
